Allergan Presents Men's Maximum Difference Data at American Society of Dermatologic Surgery Meeting
CHICAGO, Oct. 17, 2015 /PRNewswire/ -- Allergan plc presented the results of its Men's Maximum Difference study at the American Society of Dermatologic Surgery Meeting in Chicago this past weekend. Dr. Terrence Keaney presented a paper titled "Understanding the Male Perspective on Office-Based Aesthetic Procedures: Awareness, Motivating Factors, and Barriers" and Dr. Jared Jagdeo presented a paper titled "Facial Treatment Preferences in Aesthetically-Oriented Men" at open sessions on Saturday, October 17.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
There is increasing interest in facial aesthetic treatments among men; yet, there is a lack of data describing male attitudes toward age-related changes to their facial features and associated preferences for prioritizing treatment. The Men's Maximum Difference study explores men's awareness and attitudes towards age-related facial changes, office-based facial aesthetic procedures as well as their motivations and deterrents to undergoing these procedures.
The study surveyed 600 injectable-naive, but aesthetically-oriented men between the ages of 30 and 65. Respondents indicated on a six-point scale how bothered they were by the appearance of 16 facial features. Subjects were also asked if they currently have an aesthetic healthcare provider (dermatologist or plastic surgeon), what signs of facial aging they would be comfortable speaking with their physician about and what aesthetic procedures they have heard of or tried. The participants were also asked to identify their reasons why they would or would not consider an injectable treatment.
The Maximum Difference Scaling System was used to explore the following: which facial features were most likely to be prioritized for treatment, the correlation between the facial features that bothered them and the areas of treatment preference and age-related differences in treatment preference categorized in five-year age cohorts.
43% of respondents currently see a dermatologist and 4% see a plastic surgeon, with 64% of those having seen their provider within the last year. Most men in the survey were open to talking to their physician about facial wrinkles, hair loss/balding and their periorbital area. However, they responded as being unlikely to talk about a red complexion, acne scarring or broken capillaries on the face.
Among respondents, crow's feet and tear troughs were rated as the most likely to be treated first (each had 80% of first preferences) followed by forehead lines (74%) double chin (70%), glabellar lines (60%), oral commissures (55%), and chin (51%). In comparison, the features rated as the least likely to be treated first were thinning eyelashes (14%), lip volume (15%), and perioral lines (23%). The most bothersome features were tear troughs, double chin, crow's feet lines and forehead lines respectively. There was a strong correlation between the facial areas that bothered respondents most and the areas of treatment priority.
Additionally, the awareness of facial aesthetic procedures among men varied, ranging from high awareness (>90%) for plastic surgery, liposuction and hair transplant surgery to lower awareness (39%) for dermal fillers. The trial rate for all procedures was low (2% - 6%). The primary motivators for considering a facial aesthetic injectable were to "look good for my age" (70%) and to "look more youthful" (51%). Other reasons were cited less than 20% of the time, and these trends were consistent between older and younger respondents. The main barriers to undergoing injectable treatments in the next two years include concerns of cost (42%), concerned they won't look natural (41%), side effects and safety (46%), injecting a foreign substance into their body (45%) and thinking they did not need it yet (47%).
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 (such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
CONTACTS:
Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(862) 261-7558
Ember Garrett
(714) 246-3525
SOURCE Allergan plc
Share this article